Grindeks had already previously successfully cooperated with the WHO. In 2008, thanks to cooperation partners positive references of the high quality of oxytocin produced by Grindeks, the WHO invited Grindeks to participate in the project during which the company made a monograph on the quality of oxytocin. The WHO uses the monograph for product quality assessment in various projects.

“Cooperation with the WHO is a high evaluation of the quality of our manufactured production and our employees’ professionalism. This cooperation opens up promising opportunities for us to become one of the most notable oxytocin manufacturers in the world,” said Juris Bundulis, the Chairman of the Board of JSC Grindeks.

The product’s registration in highly demanding countries in terms of quality standards – the U.S. and Australia – is another aspect to confirm the high quality of oxytocin by Grindeks.

Oxytocin is one of the vertically integrated products by Grindeks, namely, the company produces both the active pharmaceutical ingredient and the final dosage form – injection. Thanks to successful marketing and sales strategy the demand for the product is highly increasing. In the first half year of 2015 the total volume of oxytocin sales was 1.3 million euros and has increased by 10% in comparison to oxytocin sales results in the first half year of 2014.

Oxytocin is a hormone that is used as a medication to facilitate childbirth, reduce postpartum bleeding, as well as to stimulate breastfeeding.